MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Neuroprotective agents"

  • 2017 International Congress

    Neuroprotective Potency of Tetrahydroisoquinoline a Novel Ayurveda Molecule in Experimental Parkinson’s Disease

    R. Banerjee, D. Nthenge-Ngumbau, R. Singh, P. Jaisankar, K. Mohanakumar, S. Biswas (Kolkata, India)

    Objective: Tetrahydroisoquinoline (TIQ) an identified alkaloid from ancient Indian ‘Ayurveda’ medicine for Parkinson’s disease (PD) was tested for neuroprotection in a cellular system and a…
  • 2017 International Congress

    Multi-modal retention in a phase III clinical trial in early Parkinson disease (STEADY-PD III)

    B. Greco, T. Simuni, J. Denmark, S. Henderson, J. Lowell, S. Sharma, C. Tarolli, D. Young, K. Biglan (Rochester, NY, USA)

    Objective: To evaluate novel retention strategies in an ongoing phase 3 clinical trial in individuals with Parkinson disease (PD) Background: Adequate participant retention is a…
  • 2017 International Congress

    CB2R agonist AM1241 reverses the development of MPTP-induced PD and activates the regeneration of DA neurons

    R. Zhu (Shanghai, China)

    Objective: A promising and potential direction to treat PD is to develop new non-dopaminergic drugs without producing dyskinesia, as well as arresting and even reversing…
  • 2017 International Congress

    AAV-mediated over-expression of VEGF-B in PINK1 gene knockout rats increases striatal dopamine content

    T. Falk, M. Bartlett, D. Muller, B. Silashki, D. Farrell, K. Parent, M. Heien, S. Sherman (Tucson, AZ, USA)

    Objective: To evaluate overexpression of the neuroprotective vascular endothelial growth factor B (VEGF-B) in a genetic Parkinson’s disease (PD) model. Background: We have shown in…
  • 2017 International Congress

    Piperine potentiate the neuroprotective effect of quercetin against MPTP induced neurotoxicity in rats

    S. Singh, P. Kumar (Moga, India)

    Objective: (1) Quercetin is well tolerated bioflavonoid used as supplement for various disorders but problem is its low oral bioavailability and (2) Piperine is combined…
  • 2017 International Congress

    Protective effect of Myristicin against neurodegeneration in a 6-hydroxydopamine induced model of Parkinson’s disease in rats

    A. Morad Ganjeh (Karaj, Islamic Republic of Iran)

    Objective: This study examined the effect of pretreatment with Myristicin on the severity of 6-hydroxydopamine-induced Parkinsonism in Wistar rats in order to find out whether…
  • 2016 International Congress

    Identification of unique metabolite signatures in post-mortem DBS human tissue using LC-HRMS

    V. Vedam-Mai, S. Sternberg, M. Williams, T. Garrett, M.S. Okun (Gainesville, FL, USA)

    Objective: Metabolomics is applied to the study of metabolic as well as neurodegenerative diseases. We propose to utilize this technique to detect metabolic changes from…
  • 2016 International Congress

    Serum level of vitamin D3 in patients with neurodegenerative diseases compared to healthy adults and its correlation with the years spent from the initial diagnosis

    A.N. Taravari (Skopje, Macedonia)

    Objective: Vitamin D is an important factor responsible for many physiologic functions. Vitamin D deficiency is associated with increased risk of neurodegenerative disease. Background: The…
  • 2016 International Congress

    Neuronal nicotinamide-N-methyltransferase (NNMT) in Parkinson’s disease

    K. Schmeisser, A. Parker (Montreal, QC, Canada)

    Objective: Understanding the role of NNMT in initiation and progression of Parkinson's disease (PD). Background: 10-15% of all PD cases are caused by genetic factors,…
  • 2016 International Congress

    Creatine for patients with Parkinson’s disease: A meta-analysis

    A. Attia, H. Ahmed, M. Morsi, K. Awad, M. Elnenny, E. Ghanem, A. Negida (Cairo, Egypt)

    Objective: The aim of this systematic review and meta-analysis is to synthesize evidence from published randomized controlled trials (RCTs) about the efficacy of creatine for…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Survey-Based study of marijuana used in Parkinson’s Disease patients
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley